Eleison Pharmaceuticals Overview
- Founded
-
2009

- Status
-
IPO Registration
- Employees
-
2

- Latest Deal Type
-
IPO
- (Announced)
- Financing Rounds
-
4
Eleison Pharmaceuticals General Information
Description
Developer of specialty pharmaceuticals and life-saving drugs for cancer treatment. The company acquires, develops and commercializes clinical-stage drug therapies for lung, pancreatic, brain and other types of cancers, thus providing patients with a new hope to fight these rare and life-threatening diseases.
Contact Information
Website
www.eleison-pharma.com
Ownership Status
In IPO Registration
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- 100 Overlook Center
- 2nd Floor
- Princeton, NJ 08540
- United States
+1 (215) 000-0000
Eleison Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Eleison Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of specialty pharmaceuticals and life-saving drugs for cancer treatment. The company acquires, develops and co
Drug Discovery
Princeton, NJ
2
As of 2022
0000
00000000
0000
Eleison Pharmaceuticals Competitors (21)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Northwest Biotherapeutics | Corporation | Bethesda, MD | 00 | 00000 | 000000000 - | 00000 |
000000000 000000 | Venture Capital-Backed | Burlington, MA | 00 | 00000 | 0000000000 0 | 00000 |
000000 00000000000 | Formerly VC-backed | Needham, MA | 00 | 00000 | 00000000 | 00000 |
0000 00000000 | Formerly VC-backed | Stamford, CT | 00 | 00000 | 000000&0 | 00000 |
0000000 000000 | Venture Capital-Backed | Barcelona, Spain | 00 | 000.00 | 0000000000 0 | 000.00 |
Eleison Pharmaceuticals Patents
Eleison Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020262112-A1 | Combination therapeutic regimens with 1,6-dibromo-1,6-dideoxy-dulcitol | Pending | 24-Apr-2019 | 0000000000 | |
CA-3137952-A1 | Combination therapeutic regimens with 1,6-dibromo-1,6-dideoxy-dulcitol | Pending | 24-Apr-2019 | 0000000000 | |
EP-3958848-A1 | Combination therapeutic regimens with 1,6-dibromo-1,6-dideoxy-dulcitol | Pending | 24-Apr-2019 | 0000000000 | |
JP-2022529990-A | Combination treatment regimen with 1,6-dibromo-1,6-dideoxy-zlucitol | Pending | 24-Apr-2019 | 0000000000 | |
US-20220142941-A1 | Combination therapeutic regimens with 1,6-dibromo-1,6-dideoxy-dulcitol | Pending | 24-Apr-2019 | A61K31/047 |
Eleison Pharmaceuticals Executive Team (8)
Eleison Pharmaceuticals Board Members (6)
Name | Representing | Role | Since |
---|---|---|---|
00000 0000 | Self | Board Member | 000 0000 |
00000 0000000 | Capital Solutions | Board Member | 000 0000 |
0000 0000000000 00 | Self | Board Member | 000 0000 |
0000 0000000 | Self | Board Member | 000 0000 |
0000000 0000 00.0 | Self | Board Member | 000 0000 |
Eleison Pharmaceuticals Signals
Eleison Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|